MedTrace Logo

Time Schedules for Sending Invitations to Colonoscopy Screening

NCT01505972 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1600

Last updated 2012-01-10

No results posted yet for this study

Summary

The attendance rate to population based primary screening colonoscopy within NordICC trial (The Nordic-European Initiative on Colorectal Cancer, NCT00883792) in Poland is roughly 33%. The aim of this study is to compare the effect of two different time schedules for sending invitations and reminding letters to a pre-specified colonoscopy appointment. 1,600 screening naive men and women 55 to 64 years of age are randomly assigned in a 1:1 ratio to receive invitation and reminder 6 and 3 weeks (SIX and THREE group) or 4 and 2 weeks (FOUR and TWO group) prior to pre-specified screening colonoscopy appointment date. Outcome measures are participation in screening colonoscopy within 6 months from the date of invitation, response and acceptance rate before sending a reminder. The study is powered to detect 7% difference in participation in screening colonoscopy.

Conditions

Interventions

OTHER

Six and three time schedule

Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.

OTHER

Four and two time schedule

Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.

Sponsors & Collaborators

  • National Center for Research and Development, Poland

    collaborator OTHER

  • Maria Sklodowska-Curie National Research Institute of Oncology

    lead OTHER

Principal Investigators

  • Regula Jaroslaw, MD, PhD · Center of Oncology UInstitute and the Maria Sklodowska-Curie

  • Kaminski F Michal, MD · Center of Oncology Institute and the Maria Sklodowska-Curie

  • Pisera Malgorzata, Msc · Center of Oncology Institute and the Maria Sklodowska-Curie

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01505972 on ClinicalTrials.gov